



Elixir Pharmaceuticals to Present at the UBS Global Life Sciences Conference

CAMBRIDGE, Mass. – September 18, 2008 – Elixir Pharmaceuticals today announced that William K. Heiden, Chief Executive Officer of Elixir Pharmaceuticals, will present at the UBS Global Life Sciences Conference on Monday, September 22, 2008 at 9:30am Eastern Time at the Grand Hyatt Hotel in New York City.

Mr. Heiden will provide a corporate overview, as well as an update on the Company's clinical development programs.

About Elixir Pharmaceuticals

Elixir is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that modulation of specific genes can slow the aging process and increase longevity. Elixir is developing small molecule drugs that mimic these longevity responses, and these drugs will be used to treat a range of age-related diseases, including the major metabolic diseases.

The Company has two late-stage products (Metgluna™ and Glinsuna™) for the treatment of type 2 diabetes in a final phase III trial in the U.S., with NDA filing expected in 2009. In addition, the Company is developing an oral ghrelin antagonist for the treatment of metabolic disease. Elixir is also developing EX-1314, an oral drug being developed for the treatment of type 1 diabetic gastroparesis. Further, the Company's SIRT product development program is exemplary of how Elixir continues to use its understanding of the pathways which slow the aging process to identify interesting targets for the development of drugs to treat metabolic disease.

#

CONTACT: Elixir Pharmaceuticals
Gregory Perry, 617-995-7000
or

Burns McClellan for Elixir Pharmaceuticals
Media:
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or

Investors:
Susan Neath, 212-213-0006
sneath@burnsmc.com